The meningococcal vaccine candidate neisserial surface protein a (NspA) binds to factor H and enhances meningococcal resistance to complement

PLoS Pathogens

Volumn 6, Issue 7, 2010, Pages 1-20

  Lewis, Lisa A ^a   Ngampasutadol, Jutamas ^a   Wallace, Ruth ^b   Reid, Jane E A ^b   Vogel, Ulrich ^c   Ram, Sanjay ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; HEPTOSE; LIPOOLIGOSACCHARIDE; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; PROTEIN A; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; COMPLEMENT; FACTOR H BINDING PROTEIN, NEISSERIA MENINGITIDIS; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; NSPA PROTEIN, NEISSERIA; OUTER MEMBRANE PROTEIN;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CONTROLLED STUDY; DELETION MUTANT; GENE DELETION; GENE OVEREXPRESSION; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEISSERIA; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SIALYLATION; HUMAN; IMMUNOLOGY; METABOLISM;

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; HUMANS; MENINGOCOCCAL VACCINES; PROTEIN BINDING;

EID: 77957652922     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001027     Document Type: Article

References (73)

1. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129: 1307-1326.
2. Figueroa J, Andreoni J, Densen P (1993) Complement deficiency states and meningococcal disease. Immunol Res 12: 295-311.
3. Figueroa JE, Densen P (1991) Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4: 359-395.
4. Fijen CA, Kuijper EJ, te Bulte MT, Daha MR, Dankert J (1999) Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 28: 98-105.
5. Ross SC, Densen P (1984) Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63: 243-273.
6. Jarvis GA, Vedros NA (1987) Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun 55: 174-180.
7. Uria MJ, Zhang Q, Li Y, Chan A, Exley RM, et al. (2008) A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med 205: 1423-1434.
8. Sa ECC, Griffiths NJ, Virji M (2010) Neisseria meningitidis Opc invasin binds to the sulphated tyrosines of activated vitronectin to attach to and invade human brain endothelial cells. PLoS Pathog 6: e1000911.
9. Virji M, Griffiths NJ. Binding of Opc to vitronectin contributes to increased serum resistance of Neisseria meningitidis isolates. In: van Alphen L, van der Ley P, van den Dobbelsteen G, eds. 2008; Rotterdam, The Netherlands, 166-167.
10. Jarva H, Ram S, Vogel U, Blom AM, Meri S (2005) Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol 174: 6299-6307.
11. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, et al. (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72: 2088-2100.
12. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, et al. (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197: 789-799.
13. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177: 501-510.
14. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, et al. (2009) Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature.
15. Pangburn MK, Schreiber RD, Muller-Eberhard HJ (1977) Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 146: 257-270.
16. Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A 73: 3268-3272.
17. Whaley K, Ruddy S (1976) Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med 144: 1147-1163.
18. Beernink PT, Granoff DM (2009) The modular architecture of meningococcal factor H-binding protein. Microbiology 155: 2873-2883.
19. Pajon R, Beernink PT, Harrison LH, Granoff DM (2009) Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine.
20. Granoff DM (2010) Review of group B meningococcal vaccines. Clin Infect Dis In Press.
21. Hammerschmidt S, Muller A, Sillmann H, Muhlenhoff M, Borrow R, et al. (1996) Capsule phase variation in Neisseria meningitidis serogroup B by slippedstrand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol 20: 1211-1220.
22. Deghmane AE, Giorgini D, Larribe M, Alonso JM, Taha MK (2002) Downregulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol 43: 1555-1564.
23. Claus H, Maiden MC, Maag R, Frosch M, Vogel U (2002) Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 148: 1813-1819.
24. Claus H, Maiden MC, Wilson DJ, McCarthy ND, Jolley KA, et al. (2005) Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191: 1263-1271.
25. Yazdankhah SP, Caugant DA (2004) Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 53: 821-832.
26. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, et al. (2006) Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176: 7566-7575.
27. Biedzka-Sarek M, Jarva H, Hyytiainen H, Meri S, Skurnik M (2008) Characterization of complement factor H binding to Yersinia enterocolitica serotype O:3. Infect Immun 76: 4100-4109.
28. Berrington AW, Tan YC, Srikhanta Y, Kuipers B, van der Ley P, et al. (2002) Phase variation in meningococcal lipooligosaccharide biosynthesis genes. FEMS Immunol Med Microbiol 34: 267-275.
29. Ram S, Ngampasutadol J, Cox AD, Blom AM, Lewis LA, et al. (2007) Heptose I glycan substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-binding protein binding and serum resistance. Infect Immun.
30. Ram S, Sharma AK, Simpson SD, Gulati S, McQuillen DP, et al. (1998) A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 187: 743-752.
31. Madico G, Ngampasutadol J, Gulati S, Vogel U, Rice PA, et al. (2007) Factor H Binding and Function in Sialylated Pathogenic Neisseriae is Influenced by Gonococcal, but Not Meningococcal, Porin. J Immunol 178: 4489-4497.
32. Mandrell RE, Kim JJ, John CM, Gibson BW, Sugai JV, et al. (1991) Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J Bacteriol 173: 2823-2832.
33. Kogan G, Uhrin D, Brisson JR, Jennings HJ (1997) Structural basis of the Neisseria meningitidis immunotypes including the L4 and L7 immunotypes. Carbohydr Res 298: 191-199.
34. Tsang RS, Law DK, Tsai C, Ng L (2001) Detection of the lst gene in different serogroups and LOS immunotypes of Neisseria meningitidis. FEMS Microbiol Lett 199: 203-206.
35. Estabrook MM, Jack DL, Klein NJ, Jarvis GA (2004) Mannose-binding lectin binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis. J Immunol 172: 3784-3792.
36. Derrick JP, Urwin R, Suker J, Feavers IM, Maiden MC (1999) Structural and evolutionary inference from molecular variation in Neisseria porins. Infect Immun 67: 2406-2413.
37. Feavers IM, Suker J, McKenna AJ, Heath AB, Maiden MC (1992) Molecular analysis of the serotyping antigens of Neisseria meningitidis. Infect Immun 60: 3620-3629.
38. Suker J, Feavers IM, Achtman M, Morelli G, Wang JF, et al. (1994) The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol Microbiol 12: 253-265.
39. Urwin R, Fox AJ, Musilek M, Kriz P, Maiden MC (1998) Heterogeneity of the PorB protein in serotype 22 Neisseria meningitidis. J Clin Microbiol 36: 3680-3682.
40. Hou VC, Moe GR, Raad Z, Wuorimaa T, Granoff DM (2003) Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun 71: 6844-6849.
41. Moe GR, Tan S, Granoff DM (1999) Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 67: 5664-5675.
42. Welsch JA, Ram S, Koeberling O, Granoff DM (2008) Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197: 1053-1061.
43. Ripoche J, Day AJ, Harris TJ, Sim RB (1988) The complete amino acid sequence of human complement factor H. Biochem J 249: 593-602.
44. Shaughnessy J, Lewis LA, Jarva H, Ram S (2009) Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun 77: 2094-2103.
45. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, et al. (2008) Human Factor H Interacts Selectively with Neisseria gonorrhoeae and Results in Species-Specific Complement Evasion. J Immunol 180: 3426-3435.
46. Friese MA, Hellwage J, Jokiranta TS, Meri S, Peter HH, et al. (1999) FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol 36: 809-818.
47. Granoff DM, Welsch JA, Ram S (2009) Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77: 764-769.
48. Ngampasutadol J, Ram S, Blom AM, Jarva H, Jerse AE, et al. (2005) Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A 102: 17142-17147.
49. Blom AM, Hallstrom T, Riesbeck K (2009) Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol Immunol 46: 2808-2817.
50. Kraiczy P, Wurzner R (2006) Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol Immunol 43: 31-44.
51. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, et al. (2009) Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200: 379-389.
52. Martin D, Cadieux N, Hamel J, Brodeur BR (1997) Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185: 1173-1183.
53. Jones DM, Borrow R, Fox AJ, Gray S, Cartwright KA, et al. (1992) The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb Pathog 13: 219-224.
54. Mackinnon FG, Borrow R, Gorringe AR, Fox AJ, Jones DM, et al. (1993) Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model. Microb Pathog 15: 359-366.
55. McLeod Griffiss J, Brandt BL, Saunders NB, Zollinger W (2000) Structural relationships and sialylation among meningococcal L1, L8, and L3,7 lipooligosaccharide serotypes. J Biol Chem 275: 9716-9724.
56. Madico G, Ram S, Getzlaff S, Prasad A, Gulati S, et al. Sialylation of lacto-Ntetraose lipooligosaccharide in gonococci, but not meningococci, results in enhanced factor H binding: the modulatory role of gonococcal porin; 2004 September 5-September 10, 2004; Milwaukee, Wisconsin, 230.
57. Cadieux N, Plante M, Rioux CR, Hamel J, Brodeur BR, et al. (1999) Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun 67: 4955-4959.
58. Estabrook MM, Jarvis GA, McLeod Griffiss J (2007) Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect Immun 75: 1025-1033.
59. Ram S, Cox AD, Wright JC, Vogel U, Getzlaff S, et al. (2003) Neisserial lipooligosaccharide is a target for complement component C4b: Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem 278: 50853-50862.
60. Seib KL, Oriente F, Adu-Bobie J, Montanari P, Ferlicca F, et al. (2010) Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine.
61. Seib KL, Serruto D, Oriente F, Delany I, Adu-Bobie J, et al. (2009) Factor Hbinding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77: 292-299.
62. Halperin SA, Langley JM, Smith B, Wunderli P, Kaufman L, et al. (2007) Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25: 450-457.
63. Martin D, Brodeur BR, Hamel J, Couture F, de Alwis U, et al. (2000) Candidate Neisseria meningitidis NspA vaccine. J Biotechnol 83: 27-31.
64. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM (2002) Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70: 6021-6031.
65. Meri S, Jordens M, Jarva H (2008) Microbial complement inhibitors as vaccines. Vaccine 26 Suppl 8: I113-117.
66. Vogel U, Claus H, Heinze G, Frosch M (1999) Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates. Infect Immun 67: 954-957.
67. Gulati S, Cox A, Lewis LA, Michael FS, Li J, et al. (2005) Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci. Infect Immun 73: 7390-7397.
68. Lewis LA, Gipson M, Hartman K, Ownbey T, Vaughn J, et al. (1999) Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of Neisseria meningitidis DNM2. Mol Microbiol 32: 977-989.
69. Hou VC, Koeberling O, Welsch JA, Granoff DM (2005) Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 192: 580-590.
70. Gnehm HE, Pelton SI, Gulati S, Rice PA (1985) Characterization of antigens from nontypable Haemophilus influenzae recognized by human bactericidal antibodies. Role of Haemophilus outer membrane proteins. J Clin Invest 75: 1645-1658.
71. Lahm HW, Langen H (2000) Mass spectrometry: a tool for the identification of proteins separated by gels. Electrophoresis 21: 2105-2114.
72. McQuillen DP, Gulati S, Rice PA (1994) Complement-mediated bacterial killing assays. Methods Enzymol 236: 137-147.
73. Cuzick J (1985) A Wilcoxon-type test for trend. Stat Med 4: 87-90.